Morgan Stanley initiated coverage of Watson Pharmaceuticals (NYSE:WPI) with an overweight rating and $61 price target.
The bank sees 2010 EPS of $3.41, vs. consensus estimates of $3.40 per share, and 2011 EPS of $4.11, vs. consensus estimates of $4.06 per share.
Watson Pharmaceuticals, Inc. develops, manufactures, and sells generic and brand name pharmaceutical products. The Company's core focus is specialty products, nephrology, urology, and generic products.
Watson Pharmaceuticals has a potential upside of 8.4% based on a current price of $51 and an average consensus analyst price target of $55.31.
Watson Pharmaceuticals is currently above its 50-day moving average (MA) of $45.82 and above its 200-day of $42.81.
No comments:
Post a Comment